BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD

ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the clinical trial, has reviewed the initial safety data from the first cohort in the Phase I/IIa clinical trial of OpRegen®. OpRegen® is comprised of